Peptide News: A Warning Letter for a Major Compounder, and Retatrutide’s Case Now Sits With the Judges

Two updates matter this week if you’re weighing peptide or GLP-1 therapy. The FDA warned Empower Pharmacy, one of the country’s highest-volume compounders, after finding it had mass-produced “personalized” GLP-1 formulas using what looks like copy-pasted paperwork. Separately, the Seventh Circuit heard oral argument in the case deciding whether retatrutide can ever legally be compounded — though the court hasn’t ruled yet. Both turn on the same question: what separates a physician’s individualized prescription from a mass-produced one wearing a compounding label.

The FDA Warns a Major Compounder Over “Copy” GLP-1 Formulas

On September 18, 2026, the FDA sent a warning letter to Empower Clinic Services, LLC, dba Empower Pharmacy, a Houston-based compounding pharmacy and one of the largest suppliers of compounded GLP-1 products to telehealth and med spa clients nationally. It’s the pharmacy’s third warning letter from the agency.

The letter, following a November 2025 inspection, centers on two formulations: tirzepatide combined with niacinamide, and semaglutide combined with cyanocobalamin (vitamin B12). The FDA’s core finding is that these are “essentially copies” of FDA-approved drugs — the same active ingredients as Mounjaro/Zepbound and Ozempic/Wegovy, with a vitamin added. Under Section 503A of the Food, Drug & Cosmetic Act, a pharmacy can only compound something that duplicates an approved drug if a prescriber documents that the change produces a “significant difference” for that specific patient. Adding a vitamin doesn’t automatically clear that bar — the record has to show the change was made for that patient’s clinical situation, not as a standard add-on.

That’s exactly what the FDA says it didn’t find. Investigators flagged “prescriber determinations of ‘significant difference’ that appear to be repeated verbatim across many records” — language suggesting a pre-written template rather than individual clinical judgment. The letter also raised concerns about third-party prescribing platforms offering dropdown-menu justifications, and cited high monthly order volumes (figures redacted in the public letter) that FDA said were inconsistent with patient-specific compounding. Separately, it cited manufacturing gaps — incomplete media-fill testing and insufficient environmental monitoring — supporting a finding of adulteration on top of the “copy drug” issue. The FDA gave Empower 15 working days to detail corrective action, warning that failing to do so “may result in legal action without further notice, including seizure and injunction.”

Why It Matters

Empower is not a fringe operator — it’s a pharmacy telehealth companies commonly point to when promising a “vetted” or “licensed” supply chain, and a third warning letter suggests the FDA isn’t satisfied prior fixes held. Legal analysts reviewing the letter say it sharpens a standard the industry had treated loosely: adding a vitamin to a GLP-1 doesn’t by itself make it a personalized compound, and the justification has to be genuinely tied to that patient, not boilerplate. For patients, the read is blunt: a provider whose “personalization” looks the same on every chart is the exact pattern this letter says fails the legal test — regardless of whether the pharmacy filling it holds a valid state license. We covered how to vet a telehealth provider last week, and this letter is a real-world example of exactly the gap that checklist is meant to catch.

Retatrutide’s Case Now Sits With the Seventh Circuit

The other story this week is the next step in one we’ve been tracking: the Seventh Circuit heard oral argument on September 24, as scheduled, in Eli Lilly and Company v. Robert F. Kennedy, Jr. — the case over whether retatrutide is legally a “drug” or a “biologic.” We laid out the three ways the ruling could go earlier this week, and that’s still the right framework: the court could order biologic status outright (Lilly’s ask, which would permanently bar compounding), send the question back to the FDA, or side with the agency’s original position.

What’s new is simply that the argument happened, not that it resolved anything. Appeals courts typically take weeks to months to rule, and as of this writing no decision has published. We’ll report the outcome when it lands. Nothing about retatrutide’s legal status has changed meanwhile: it remains in Phase 3 trials, isn’t FDA-approved for any use, and any retatrutide sold online today is being sold illegally, whatever the marketing says.

Where the Compounding Review Stands

No movement on the broader question we’ve tracked for months. The FDA advisory committee’s July recommendation to add six peptides — BPC-157, TB-500, KPV, MOTS-C, Semax, and Epitalon — to the legal 503A compounding list is still sitting with HHS, awaiting formal action ahead of a rulemaking process analysts estimate could take eight to twelve months once it starts. No final rule, no timeline.

How to Read a Compounding Provider’s Claims Like the FDA Does

The Empower letter is a useful lens for evaluating any telehealth or compounding provider. A few questions worth asking before you sign up anywhere:

Does intake ask about your history, or does every answer lead to the same recommendation?
If a product includes an added vitamin, can the provider explain why you need it — not just that it’s in every formula they sell?
Is the pharmacy named and one you can look up?
Does the provider ever say no? A questionnaire that approves everyone isn’t individualized medicine — it’s a checkout page.

Why This Matters If You’re Considering Peptide Therapy

Physician-guided only. Every treatment plan is reviewed and prescribed by an independent physician licensed in your state, only when clinically appropriate — never approved by a dropdown menu.
Vetted, licensed U.S. pharmacies. We work with pharmacy partners held to accreditation-level standards, not just a baseline license, and track enforcement actions like this one closely.
Care plans that adapt as regulation changes. Whatever the Seventh Circuit or HHS decides, your plan follows what can be legally and safely dispensed — not what a marketing page wants to sell you.

FAQ

What did the FDA find in its warning letter to Empower Pharmacy?

That Empower’s tirzepatide/niacinamide and semaglutide/cyanocobalamin formulas were “essentially copies” of FDA-approved drugs, with prescriber justifications that appeared to be repeated boilerplate rather than individualized determinations. The letter also cited manufacturing and sterility gaps. It’s Empower’s third FDA warning letter.

Does adding a vitamin to a GLP-1 make it a legal compounded product?

Not automatically. Under Section 503A, a compounded copy of an approved drug is exempt from FDA approval only if a prescriber documents a “significant difference” for that specific patient. A standard vitamin add-on with no patient-specific justification doesn’t meet that bar, per the FDA’s letter.

Did the Seventh Circuit rule on retatrutide this week?

No. The court heard oral argument on September 24, 2026, but hasn’t issued a decision. Appellate rulings typically take weeks to months; we’ll cover the outcome once it’s published.

Is retatrutide legal to buy right now?

No. It remains in Phase 3 trials with no FDA-approved version. Any retatrutide sold online today is being sold illegally, regardless of how the court eventually classifies it.

Is BPC-157 legal to compound yet?

No. The FDA advisory committee’s July 2026 recommendation to add six peptides to the legal compounding list is still awaiting formal HHS action and rulemaking.

This article is for informational purposes only and does not constitute medical advice. Peptide therapy should only be pursued under the guidance of a licensed physician.

A Warning Letter for a Major Compounder, and Retatrutide’s Case Now Sits With the Judges